Anti-vascular endothelial growth factor therapy for malignant glioma

Current Neurology and Neuroscience Reports

Volumn 9, Issue 3, 2009, Pages 254-262

  Gerstner, Elizabeth R ^a   Sorensen, A Gregory ^b   Jain, Rakesh K ^b   Batchelor, Tracy T ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; HYDROXYUREA; IRINOTECAN; LOMUSTINE; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIONEUROTIC EDEMA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE EXPRESSION; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTESTINE PERFORATION; LEUKOENCEPHALOPATHY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; THROMBOSIS; WOUND HEALING IMPAIRMENT;

ANTIBODIES; ANTINEOPLASTIC AGENTS; GLIOMA; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64649097553     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0037-2     Document Type: Review

References (52)

1. Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Jain RK, di Tomaso E, Duda DG, et al.: Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
3. Jensen RL, Ragel BT, Whang K, Gillespie D: Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 2006, 78:233-247.
4. Forsythe JA, Jiang BH, Iyer NV, et al.: Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
5. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
6. Gomez-Manzano C, Fueyo J, Jiang H, et al.: Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 2003, 53:109-117.
7. Yoshino Y, Aoyagi M, Tamaki M, et al.: Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. Int J Oncol 2006, 29:981-987.
8. Saino M, Maruyama T, Sekiya T, et al.: Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3. Oncol Rep 2004, 12:47-52.
9. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
10. Li JL, Sainson RC, Shi W, et al.: Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007, 67:11244-11253.
11. Tsai JC, Goldman CK, Gillespie GY: Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995, 82:864-873.
12. Goldman CK, Kim J, Wong WL, et al.: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993, 4:121-133.
13. Ryuto M, Ono M, Izumi H, et al.: Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996, 271:28220-28228.
14. Morrison RS, Gross JL, Herblin WF, et al.: Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res 1990, 50:2524-2529.
15. Reiss Y, Machein MR, Plate KH: The role of angiopoietins during angiogenesis in gliomas. Brain Pathol 2005, 15:311-317.
16. Folkman A: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273-286.
17. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40.
18. Jain RK: Normalization of tumoA vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
19. Calabrese C, Poppleton H, Kocak M, et al.: A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
20. Bao S, Wu Q, Sathornsumetee S, et al.: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006, 66:7843-7848.
21. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
22. Wong ET, Hess KR, Gleason MJ, et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572-2578.
23. Sathornsumetee S, Cao Y, Marcello JE, et al.: Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008, 26:271-278.
24. Cloughesy TF, Prados MD, Wen PY, et al.: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract 2010b]. J Clin Oncol 2008, 26(Suppl).
25. Kreisl TN, Kim L, Moore K, et al.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745.
26. Sathornsumetee S, Vredenburgh J, Rich J, et al.: Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme [abstract 13008]. J Clin Oncol 2008, 26(Suppl).
27. Rich J, Desjardins A, Sathornsumetee S, et al.: Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma [abstract 2022]. J Clin Oncol 2008, 26(Suppl).
28. Lai A, Filka E, McGibbon B, et al.: Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71:1372-1380.
29. HolasA J, Davis S, Papadopoulos N, et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99:11393-11398.
30. De Groot J, Wen P, Lamborn K, et al.: Phase II single arm trial of aflibercept in patients with recurrent temozolomideresistant glioblastoma: NABTC 0601 [abstract 2020]. J Clin Oncol 2008, 26(Suppl).
31. Wachsberger PR, Burd R, Cardi C, et al.: VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007, 67:1526-1537.
32. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
33. Wood JM, Bold G, Buchdunger E, et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178-2189.
34. Goldbrunner RH, Bendszus M, Sasaki M, et al.: Vascular endothelial growth factor-driven glioma growth and vascularization in an orthotopic rat model monitored by magnetic resonance imaging. Neurosurgery 2000, 47:921-929; discussion 929-930.
35. Conrad C, Friedman H, Reardon D, et al.: A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM) [abstract 1512]. ASCO Annu Meeting Proc (Post-Meeting Edition) 2004, 22(Suppl):1512.
36. Reardon D, Friedman H, Yung WKA, et al.: A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM) [abstract 1513]. ASCO Annu Meeting Proc (Post-Meeting Edition) 2004, 22(Suppl):1513.
37. KirkpatrPck J, Rich J, Vredenburgh J, et al.: Final report: phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG) [abstract 2057]. J Clin Oncol 2008, 26(Suppl).
38. Nabors L, Rosenfeld M, Chamberlain M, et al.: A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). ASCO Annu Meeting Proc 2007, 25(Suppl):2058.
39. Rich JN, Sathornsumetee S, Keir ST, et al.: ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005, 11:8145-8157.
40. Sandstrom M, Johansson M, Bergstrom P, et al.: Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J Neurooncol 2008, 88:1-9.
41. TrAxler P, Allegrini PR, Brandt R, et al.: AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004, 64:4931-4941.
42. Goudar RK, Shi Q, Hjelmeland MD, et al.: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005, 4:101-112.
43. Reardon D, Cloughesy T, Conrad C, et al.: A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients [abstract 3063]. ASCO Annu Meeting Proc 2005, 23(Suppl):3063.
44. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
45. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485.
46. Drevs J, Muller-Driver R, Wittig C, et al.: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002, 62:4015-4022.
47. Pope WB, Lai A, Nghiemphu P, et al.: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66:1258-1260.
48. Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67:323-326.
49. Kim JH, Chung YG, Kim CY, et al.: Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci 2004, 19:879-886.
50. Rubenstein JL, Kim J, Ozawa T, et al.: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2:306-314.
51. Kunkel P, Ulbricht U, Bohlen P, et al.: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
52. Gomez-Manzano C, Holash J, Fueyo J, et al.: VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 2008, 10:940-945.